Shibany P Taormina1, Matthew P Galloway, David R Rosenberg. 1. *Department of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, Detroit, MI; †Department of Psychiatry, Children's Hospital of Michigan, Detroit, MI; ‡Department of Anesthesiology, Wayne State University School of Medicine, Detroit, MI.
Abstract
OBJECTIVE: Treatment of obsessive-compulsive disorder (OCD) is complicated by comorbid psychiatric disorders. Successful treatment of 2 pediatric patients with severe OCD and comorbid attention deficit/hyperactivity disorder (ADHD) is described. METHOD: A report on 2 pediatric clinical cases (Ages 9 and 10) with comorbid OCD and ADHD was used to describe response to medication management through the serotonin transporter inhibitor, sertraline, and the noradrenergic α2A receptor agonist, guanfacine, along with cognitive behavioral therapy. RESULTS: Cognitive behavioral therapy combined with titrated doses of the serotonin transporter inhibitor, sertraline, and the noradrenergic α2A receptor agonist, guanfacine resolved OCD symptoms and the underlying ADHD. CONCLUSION: The novel observations support a focused psychological and pharmacological approach to successful treatment of complex symptoms in patients with comorbid OCD and ADHD. Limitations to generalizability are discussed.
OBJECTIVE: Treatment of obsessive-compulsive disorder (OCD) is complicated by comorbid psychiatric disorders. Successful treatment of 2 pediatric patients with severe OCD and comorbid attention deficit/hyperactivity disorder (ADHD) is described. METHOD: A report on 2 pediatric clinical cases (Ages 9 and 10) with comorbid OCD and ADHD was used to describe response to medication management through the serotonin transporter inhibitor, sertraline, and the noradrenergic α2A receptor agonist, guanfacine, along with cognitive behavioral therapy. RESULTS: Cognitive behavioral therapy combined with titrated doses of the serotonin transporter inhibitor, sertraline, and the noradrenergic α2A receptor agonist, guanfacine resolved OCD symptoms and the underlying ADHD. CONCLUSION: The novel observations support a focused psychological and pharmacological approach to successful treatment of complex symptoms in patients with comorbid OCD and ADHD. Limitations to generalizability are discussed.
Authors: Brooke Sheppard; Denise Chavira; Amin Azzam; Marco A Grados; Paula Umaña; Helena Garrido; Carol A Mathews Journal: Depress Anxiety Date: 2010-07 Impact factor: 6.505
Authors: S Walitza; H Zellmann; B Irblich; K W Lange; O Tucha; U Hemminger; K Wucherer; V Rost; H Reinecker; C Wewetzer; A Warnke Journal: J Neural Transm (Vienna) Date: 2008-01-16 Impact factor: 3.575
Authors: Miguel A Fullana; David Mataix-Cols; Avshalom Caspi; Honalee Harrington; Jessica R Grisham; Terrie E Moffitt; Richie Poulton Journal: Am J Psychiatry Date: 2009-02-02 Impact factor: 18.112
Authors: Maria Alice de Mathis; Juliana B Diniz; Ana G Hounie; Roseli G Shavitt; Victor Fossaluza; Ygor Ferrão; James F Leckman; Carlos de Bragança Pereira; Maria Conceição do Rosario; Eurípedes C Miguel Journal: Eur Neuropsychopharmacol Date: 2012-08-22 Impact factor: 4.600
Authors: Daniel Lustberg; Alexa F Iannitelli; Rachel P Tillage; Molly Pruitt; L Cameron Liles; David Weinshenker Journal: Psychopharmacology (Berl) Date: 2020-04-20 Impact factor: 4.530